Details
Stereochemistry | RACEMIC |
Molecular Formula | C12H18ClNO |
Molecular Weight | 227.73 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)NCC(O)C1=C(Cl)C=CC=C1
InChI
InChIKey=YREYLAVBNPACJM-UHFFFAOYSA-N
InChI=1S/C12H18ClNO/c1-12(2,3)14-8-11(15)9-6-4-5-7-10(9)13/h4-7,11,14-15H,8H2,1-3H3
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.mylan.co.jp/-/media/MylanJP/documents/epd_products/interview_updated/if_hokunalin.pdf
Curator's Comment: description was created based on several sources, including:
http://www.mylan.co.jp/-/media/MylanJP/documents/epd_products/interview_updated/if_hokunalin.pdf
Tulobuterol is a long-acting beta2-adrenergic receptor agonist. Tulobuterol has almost no effects on blood pressure and heart rate and is highly selective for the tracheal muscle. It is indicated to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, bronchitis, chronic obstructive pulmonary disease (COPD) and emphysema. Serious side effects detected were: tremor, palpitations and serum potassium level decrease.
CNS Activity
Sources: http://www.mylan.co.jp/-/media/MylanJP/documents/epd_products/interview_updated/if_hokunalin.pdf
Curator's Comment: Known to be CNS penetrant in rats. Human data not available.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Hokunalin Approved UseIt is usually used to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, acute bronchitis, chronic bronchitis, or emphysema. Launch Date3.68064004E11 |
|||
Palliative | Hokunalin Approved UseIt is usually used to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, acute bronchitis, chronic bronchitis, or emphysema. Launch Date3.68064004E11 |
|||
Palliative | Hokunalin Approved UseIt is usually used to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, acute bronchitis, chronic bronchitis, COPD or emphysema. Launch Date3.68064004E11 |
|||
Palliative | Hokunalin Approved UseIt is usually used to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, acute bronchitis, chronic bronchitis, or emphysema. Launch Date3.68064004E11 |
PubMed
Title | Date | PubMed |
---|---|---|
Induction and reduction of muscle tremor upon acute and repeated administration of the beta 2-agonists terbutaline, salbutamol and tulobuterol. | 1987 Dec |
|
Quantitative determination of clenbuterol, salbutamol and tulobuterol enantiomers by capillary electrophoresis. | 2001 Feb |
|
Clinical characteristics of asthmatic patients prescribed various beta-agonist metered-dose inhalers at Yamagata University Hospital. | 2001 Jan |
|
Effects of sustained-release tulobuterol on asthma control and beta-adrenoceptor function. | 2002 Dec |
|
[Development of transdermal formulation of tulobuterol for the treatment of bronchial asthma]. | 2002 Jan |
|
Effects of a nitro compound patch on neuropathy in Churg-Strauss syndrome. | 2003 Jul |
|
[Pharmacological action and clinical aspects of salmeterol]. | 2003 Sep |
|
Clinical evaluation of a transdermal therapeutic system of the beta2-agonist tulobuterol in patients with mild or moderate persistent bronchial asthma. | 2004 |
|
[Clinical evaluation of tulobuterol patch in patients with mild or moderate persistent bronchial asthma-effects of long-term treatment on airway inflammation and hypersensitivity]. | 2004 Feb |
|
Evaluation of MISPE for the multi-residue extraction of beta-agonists from calves urine. | 2004 May 5 |
|
Alteration of the circadian rhythm in peak expiratory flow of nocturnal asthma following nighttime transdermal beta2-adrenoceptor agonist tulobuterol chronotherapy. | 2005 |
|
High-performance liquid chromatography electrospray ionization mass spectrometry determination of tulobuterol in rabbit's plasma. | 2005 Feb 7 |
|
Determination of beta-agonist residues in bovine urine using liquid chromatography-tandem mass spectrometry. | 2005 Jan-Feb |
|
Differential effects of short-acting beta2-agonists on human granulocyte functions. | 2006 |
|
The use of patch formulation of tulobuterol, a long-acting beta2-adrenoreceptor agonist, in the treatment of severe pediatric asthma. | 2006 Jun |
|
Immunology and homeopathy. 3. Experimental studies on animal models. | 2006 Jun |
|
Comparison of the clinical efficacy of salmeterol and sustained-release tulobuterol (patch) on inadequately controlled asthma patients on inhaled corticosteroids. | 2006 Sep |
|
Treatment with beta2-adrenoceptor agonist in vivo induces human clock gene, Per1, mRNA expression in peripheral blood. | 2007 |
|
Clinical efficacy of the transdermal tulobuterol patch in patients with chronic obstructive pulmonary disease: a comparison with slow-release theophylline. | 2008 |
|
Characterization of monolithic matrix patch system containing tulobuterol. | 2008 Aug |
|
Anti-inflammatory effects and clinical efficacy of theophylline and tulobuterol in mild-to-moderate chronic obstructive pulmonary disease. | 2008 Dec |
|
[Simultaneous determination of nine beta-agonist residues in animal derived foods by ultra performance liquid chromatography-tandem mass spectrometry]. | 2008 Nov |
|
Cough and transdermal long-acting beta2 agonist in Japan. | 2008 Oct |
|
Tulobuterol patch maintains diaphragm muscle contractility for over twenty-four hours in a mouse model of sepsis. | 2009 Aug |
|
Effects of the addition of Beta2-agonist tulobuterol patches to inhaled corticosteroid in patients with asthma. | 2009 Dec |
|
Comparison of adherence and efficacy between inhaled salmeterol and transdermal tulobuterol patch in elderly patients with chronic obstructive pulmonary disorder. | 2009 May |
|
Comparative study of skin permeation profiles between brand and generic tulobuterol patches. | 2010 |
|
Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories. | 2010 Apr |
|
Simultaneous determination of beta2-agonists in human urine by fast-gas chromatography/mass spectrometry: method validation and clinical application. | 2010 Apr |
|
[Determination of fifteen beta-agonists in animal urine by high performance liquid chromatography-tandem mass spectrometry]. | 2010 Aug |
|
Effect of porous silica on sustained release behaviors of pH sensitive pluronic F127/poly(acrylic acid) hydrogels containing tulobuterol. | 2010 Oct 15 |
Patents
Sample Use Guides
In general, for adults and children aged 9 or older, apply 2 mg of the tape to the chest, back, or upper arm, once daily. For children aged 6 months to 2 years, apply 0.5 mg of the tape to the chest, back, or upper arm, once daily. For children aged 3 to 8 years, apply 1 mg of the tape to the chest, back, or upper arm, once daily. This preparation contains 2 mg of the active ingredients in a piece of tape.
Route of Administration:
Transdermal
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C319
Created by
admin on Fri Dec 15 15:14:02 UTC 2023 , Edited by admin on Fri Dec 15 15:14:02 UTC 2023
|
||
|
NCI_THESAURUS |
C48149
Created by
admin on Fri Dec 15 15:14:02 UTC 2023 , Edited by admin on Fri Dec 15 15:14:02 UTC 2023
|
||
|
WHO-VATC |
QR03AC11
Created by
admin on Fri Dec 15 15:14:02 UTC 2023 , Edited by admin on Fri Dec 15 15:14:02 UTC 2023
|
||
|
WHO-ATC |
R03CC11
Created by
admin on Fri Dec 15 15:14:02 UTC 2023 , Edited by admin on Fri Dec 15 15:14:02 UTC 2023
|
||
|
WHO-VATC |
QR03CC11
Created by
admin on Fri Dec 15 15:14:02 UTC 2023 , Edited by admin on Fri Dec 15 15:14:02 UTC 2023
|
||
|
WHO-ATC |
R03AC11
Created by
admin on Fri Dec 15 15:14:02 UTC 2023 , Edited by admin on Fri Dec 15 15:14:02 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
38967
Created by
admin on Fri Dec 15 15:14:02 UTC 2023 , Edited by admin on Fri Dec 15 15:14:02 UTC 2023
|
PRIMARY | RxNorm | ||
|
5606
Created by
admin on Fri Dec 15 15:14:02 UTC 2023 , Edited by admin on Fri Dec 15 15:14:02 UTC 2023
|
PRIMARY | |||
|
DB12248
Created by
admin on Fri Dec 15 15:14:02 UTC 2023 , Edited by admin on Fri Dec 15 15:14:02 UTC 2023
|
PRIMARY | |||
|
C152783
Created by
admin on Fri Dec 15 15:14:02 UTC 2023 , Edited by admin on Fri Dec 15 15:14:02 UTC 2023
|
PRIMARY | |||
|
758643
Created by
admin on Fri Dec 15 15:14:02 UTC 2023 , Edited by admin on Fri Dec 15 15:14:02 UTC 2023
|
PRIMARY | |||
|
SUB11365MIG
Created by
admin on Fri Dec 15 15:14:02 UTC 2023 , Edited by admin on Fri Dec 15 15:14:02 UTC 2023
|
PRIMARY | |||
|
41570-61-0
Created by
admin on Fri Dec 15 15:14:02 UTC 2023 , Edited by admin on Fri Dec 15 15:14:02 UTC 2023
|
PRIMARY | |||
|
4564
Created by
admin on Fri Dec 15 15:14:02 UTC 2023 , Edited by admin on Fri Dec 15 15:14:02 UTC 2023
|
PRIMARY | |||
|
591I9SU0F7
Created by
admin on Fri Dec 15 15:14:02 UTC 2023 , Edited by admin on Fri Dec 15 15:14:02 UTC 2023
|
PRIMARY | |||
|
DTXSID7048457
Created by
admin on Fri Dec 15 15:14:02 UTC 2023 , Edited by admin on Fri Dec 15 15:14:02 UTC 2023
|
PRIMARY | |||
|
TULOBUTEROL
Created by
admin on Fri Dec 15 15:14:02 UTC 2023 , Edited by admin on Fri Dec 15 15:14:02 UTC 2023
|
PRIMARY | |||
|
m11261
Created by
admin on Fri Dec 15 15:14:02 UTC 2023 , Edited by admin on Fri Dec 15 15:14:02 UTC 2023
|
PRIMARY | Merck Index | ||
|
100000091817
Created by
admin on Fri Dec 15 15:14:02 UTC 2023 , Edited by admin on Fri Dec 15 15:14:02 UTC 2023
|
PRIMARY | |||
|
CHEMBL1159717
Created by
admin on Fri Dec 15 15:14:02 UTC 2023 , Edited by admin on Fri Dec 15 15:14:02 UTC 2023
|
PRIMARY | |||
|
C010809
Created by
admin on Fri Dec 15 15:14:02 UTC 2023 , Edited by admin on Fri Dec 15 15:14:02 UTC 2023
|
PRIMARY | |||
|
2782
Created by
admin on Fri Dec 15 15:14:02 UTC 2023 , Edited by admin on Fri Dec 15 15:14:02 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)